Latest Press

Oscotec and Beactica Therapeutics announce license and collaboration agreement to...

02 Mar 2021

Read more
Latest Publication

Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase

22 Feb 2021

Read more
Latest Event

BioEquity Europe 2021

17 May 2021

Read more

We believe in our ability to improve patients’ lives through our passion for science.

With informed and creative minds we innovate novel small molecule modulators to become next-generation breakthrough therapies for life threatening conditions.

Learn More

Drug Discovery Platform

Our platform gives us the power to identify and develop allosteric modulators that targets disease-related proteins in novel ways.

Beactica's fragment-based drug discovery platform is based on state-of-the-art SPR biosensor technology that is augmented by proprietary compound collections, methodology, algorithms and experimental designs. This powerful combination enables us to achieve pioneering goals beyond the expected.

Learn More

Beactica Therapeutics presentation at NLSDays 2018

Beactica's CEO, Dr Per Källblad, gives presentation entitled "Targeting LSD1 in aggressive brain tumors" at Nordic Life Science Days (NLSDays) in Stockholm (10-12 Sep 2018)

Stay Updated

Sign up for the Beactica newsletter to receive our latest news and updates

This website uses cookies to improve your user experience. By continuing to browse this site, you agree to our use of cookies. More information. Ok!